2.60
1.17%
0.03
アフターアワーズ:
2.57
-0.03
-1.15%
前日終値:
$2.57
開ける:
$2.51
24時間の取引高:
100,000
Relative Volume:
0.45
時価総額:
$20.09M
収益:
-
当期純損益:
$-32.54M
株価収益率:
-13.00
EPS:
-0.2
ネットキャッシュフロー:
$-29.06M
1週間 パフォーマンス:
-6.81%
1か月 パフォーマンス:
-38.79%
6か月 パフォーマンス:
-83.76%
1年 パフォーマンス:
-86.84%
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
CTXR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
2.60 | 20.09M | 0 | -32.54M | -29.06M | -0.22 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 5.1% – Here’s What Happened - Defense World
Citius Pharmaceuticals stock hits 52-week low at $2.52 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - The Eastern Progress Online
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
Analysts Hunt for Undervalued Biotech Stocks - Marketscreener.com
Citius Pharmaceuticals (FRA:47N0) Enterprise Value : €9.75 Mil (As of Nov. 28, 2024) - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) 3-Year EPS without NRI Gr - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Cyclically Adjusted Reven - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals Appoints John Laffey to the ARDS Scientific Advisory Board - Marketscreener.com
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals, Inc. Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals, Inc. Appoints Jaime Bartushak as the Chief Financial Officer and Principal Financial Officer - Marketscreener.com
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 - Marketscreener.com
Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Marketscreener.com
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits - Quantisnow
Citius Pharma progresses with FDA on Mino-Lok approval By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals (NASDAQ:CTXR) Earns Hold Rating from D. Boral Capital - Defense World
Citius Pharma progresses with FDA on Mino-Lok approval - Investing.com India
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval - PR Newswire
Citius Pharma shares hit new low after reverse stock split - Kursiv Media
Citius Pharmaceuticals Stock Set to Reverse Split on Tuesday, November 26th (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split - citybiz
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - The Malaysian Reserve
Citius Pharmaceuticals announces 1-for-25 reverse stock split - MSN
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Citius Pharmaceuticals stock hits 52-week low at $0.16 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.16 - Investing.com India
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants - StockTitan
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com
Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat
What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World
Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com
Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia
Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat
Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
Citius Pharmaceuticals Inc (CTXR) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Webb Carol | Director |
Mar 04 '24 |
Option Exercise |
0.01 |
12,071 |
181 |
12,071 |
大文字化:
|
ボリューム (24 時間):